Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1861-1868

  Masiá, Mar ^a,b   Robledano, Catalina ^a   López, Natividad ^a   Escolano, Clara ^a   Gutiérrez, Félix ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Atherosclerosis; Hepatitis C therapy; ICAM; Inflammation; VCAM

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; FIBRINOGEN; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA;

ADULT; ANTIATHEROGENIC ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIXED INFECTION; OXIDATIVE STRESS; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 79960468087     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr202     Document Type: Article

References (11)

1. Bedimo R, Westfall AO, Mugavero M et al. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010; 11: 462-8.
2. Freiberg MS, Cheng DM, Kraemer KL et al. The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 2007; 21: 193-7.
3. Butt AA, Xiaoqiang W, Budoff M et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225-32.
4. Ishizaka N, Ishizaka Y, Takahashi E et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359: 133-5.
5. Arcari CM, Nelson KE, Netski DM et al. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006; [43:] e53-6.
6. Tien PC, Schneider MF, Cole SR et al. Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS 2009; 23: 1781-4.
7. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
8. Masiá M, Bernal E, Padilla S et al. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2007; 195: 167-71.
9. LoIacono O,García-Monzón C, Almasio P. et al. Solubleadhesionmolecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-α. Aliment Pharmacol Ther 1998; 12: 1091-9.
10. Itoh Y, Okanoue T, Ohnishi N et al. Serumlevels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1999; 94: 1332-40.
11. Kalabay L, Nemesanszky E, Csepregi A et al. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b. Int Immunol 2004; 16: 51-4.